Price T Rowe Associates Inc Intra Cellular Therapies, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,042,455 shares of ITCI stock, worth $87 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,042,455

Previous 1,428,410 27.02%

Holding current value

$87 Million

Previous $97.8 Million 22.03%

% of portfolio

0.01%

Previous 0.01%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$67.99 - $80.84 $26.2 Million - $31.2 Million	-385,955 Reduced 27.02%	1,042,455 $76.3 Million
Q2 2024 Aug 14, 2024	BUY	$64.76 - $79.84 $14.5 Million - $17.9 Million	224,442 Added 18.64%	1,428,410 $97.8 Million
Q1 2024 May 15, 2024	SELL	$64.37 - $75.65 $3.66 Million - $4.31 Million	-56,929 Reduced 4.51%	1,203,968 $83.3 Million
Q4 2023 Feb 14, 2024	BUY	$46.37 - $73.65 $28 Million - $44.5 Million	604,328 Added 92.04%	1,260,897 $90.3 Million
Q3 2023 Nov 14, 2023	BUY	$52.09 - $64.1 $10,990 - $13,525	211 Added 0.03%	656,569 $34.2 Million
Q2 2023 Aug 14, 2023	BUY	$54.67 - $66.44 $6.15 Million - $7.47 Million	112,424 Added 20.67%	656,358 $41.6 Million
Q1 2023 May 15, 2023	BUY	$43.8 - $56.99 $516,708 - $672,311	11,797 Added 2.22%	543,934 $29.5 Million
Q4 2022 Feb 14, 2023	BUY	$44.07 - $54.45 $7.98 Million - $9.87 Million	181,181 Added 51.62%	532,137 $28.2 Million
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $13.2 Million - $18.6 Million	310,214 Added 761.41%	350,956 $16.3 Million
Q2 2022 Aug 15, 2022	BUY	$43.0 - $65.64 $44,720 - $68,265	1,040 Added 2.62%	40,742 $2.33 Million
Q1 2022 May 16, 2022	BUY	$38.74 - $62.09 $136,093 - $218,122	3,513 Added 9.71%	39,702 $2.43 Million
Q4 2021 Feb 14, 2022	SELL	$35.2 - $53.42 $152,521 - $231,468	-4,333 Reduced 10.69%	36,189 $1.89 Million
Q3 2021 Nov 15, 2021	BUY	$28.72 - $42.49 $122,892 - $181,814	4,279 Added 11.81%	40,522 $1.51 Million
Q2 2021 Aug 16, 2021	SELL	$29.3 - $44.5 $118,547 - $180,047	-4,046 Reduced 10.04%	36,243 $1.48 Million
Q1 2021 May 17, 2021	BUY	$30.8 - $39.51 $271,009 - $347,648	8,799 Added 27.94%	40,289 $1.37 Million
Q4 2020 Feb 16, 2021	BUY	$23.34 - $32.22 $734,976 - $1.01 Million	31,490 New	31,490 $1 Million

Others Institutions Holding ITCI

# of Institutions

377

Shares Held

84.1M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.88B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Intra Cellular Therapies, Inc. Transaction History